Clinical Core

项目摘要 急性肾损伤（阿基）是一个公共卫生问题，直接影响临床和以患者为中心的结局， 以及医疗资源利用和政策。认识到在阿基方面缺乏突破性发现， UAB-UCSD奥布莱恩临床核心（核心A）旨在减少 研究者进行有效的临床和转化研究的障碍， 基础设施，以促进临床前，临床和行业研究人员的合作项目。核心A将 通过定制的项目网关提供多方面的咨询，访问临床数据库， 现有的生物储存库，以及新的生物信息学和计算技术，如U-BRITE和 Nightingale与临床和转化科学合作开展数字协作 两个机构的奖项（CTSA）计划，用于协调和询问大数据，重点是 阿基的个性化治疗具体而言，核心A将促进电子商务的协作数字化 健康记录（EHR）数据采集、转换、验证和询问。总体目标是 促进将实验室发现转化为影响人类阿基的应用。具体目标是 结构如下。在目标1中，我们将提供AKI风险患者或阿基患者的临床数据， 咨询他们的使用。具体而言，我们将提供对先前临床研究的精选临床数据的访问 由核心A（目标1A）托管，并提供对EHR中新的协调真实世界数据的访问， 阿基的流行病学监测（例如，阿基发病率、风险因素和结局）和新的临床研究， 包括但不限于阿基风险分类、亚表型和模拟试验（Aim 1B）。在目标2中， 将提供获取AKI风险患者或AKI患者生物标本的途径，并提供使用咨询。具体地说， 我们将提供Core A（Aim 2A）先前研究的生物标本。在目标2B中，我们将提供 一个新的平台，将有AKI风险或患有阿基的患者的生物样本与EHR数据联系起来。核心A将具有动态 与临床前核心、资源开发核心和 奥布莱恩肾脏协会。在这个U 54应用程序中，我们将建立在我们的专业知识和既定的成功 通过我们目前资助的奥布莱恩中心P30奖证明。鉴于我们的承诺和专业知识， 我们相信，核心A将为不断增长的研究界提供创新的资源， AKI相关研究

Project Summary Acute kidney injury (AKI) is a public health concern with direct impact on clinical and patient-centered outcomes, and healthcare resource utilization and policy. Recognizing the paucity of breakthrough discoveries in AKI and the growing burden of this condition, the UAB-UCSD O’Brien Clinical Core (Core A) is designed to reduce the barriers for investigators to conduct effective clinical and translational research by providing a robust infrastructure to promote collaborative projects across pre-clinical, clinical and industry researchers. Core A will provide multifaceted consultation through a customized Project Gateway, access to clinical databases, available biorepositories, and novel bioinformatics and computational technologies such as the U-BRITE and Nightingale collaborative digital workspaces in partnership with the Clinical and Translational Science Awards (CTSA) programs at both institutions for the harmonization and interrogation of big data with a focus on personalized medicine in AKI. Specifically, Core A will facilitate collaborative digital workspaces for electronic health record (EHR) data acquisition, transformation, validation, and interrogation. The overarching goal is to catalyze the translation of bench discoveries to applications that impact human AKI. The Specific Aims are structured as follows. In Aim 1, we will provide access to clinical data of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to curated clinical data from prior clinical studies hosted by Core A (Aim 1A) and provide access to new harmonized real-world data from the EHR to support epidemiological surveillance of AKI (e.g., AKI incidence, risk factors and outcomes) and novel clinical research, including but not limited to AKI risk-classification, sub-phenotyping, and simulated trials (Aim 1B). In Aim 2, we will provide access to biospecimens of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to biospecimens from prior studies hosted by Core A (Aim 2A). In Aim 2B we will provide a novel platform to link biospecimens of patients at risk for or with AKI with EHR data. Core A will have dynamic communications and collaborations with the Pre-Clinical Core, the Resource Development Core, and the O’Brien Kidney Consortium. In this U54 application, we will build upon our expertise and established successes demonstrated through our currently funded O’Brien Center P30 award. Given our commitment and expertise, we are confident that Core A will provide innovative resources to the growing research community interested in AKI-related research.